Major hypertriglyceridemia in HIV-infected patients on antiretroviral therapy: A role of the personal and family history

被引:3
作者
Bollens, D
Guiguet, M
Tangre, P
Rollinat, L
Rachline, A
Meynard, JL
Girard, PM
Benlian, P
Meyohas, MC
机构
[1] Hop St Antoine, Infect Dis Unit, F-75571 Paris 12, France
[2] Hop St Antoine, INSERM, U538, Dept Biochem, F-75571 Paris, France
[3] INSERM, U444, Paris, France
关键词
D O I
10.1007/s15010-004-3155-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Our aim was to identify factors predisposing HIV-infected patients on long-term antiretroviral therapy (ART) to major hypertriglyceridemia (HTG). Patients and Methods: We conducted a retrospective, case-control study involving 76 HIV-infected patients with HTG, defined by 12-hour fasting plasma triglyceride (TG) >4.5 mmol/l on at least one occasion, and 150 HIV-infected matched control patients with TG consistently below 1.8 mmol/l. Results: Patients coinfected by the hepatitis C virus appeared to be protected from HTG. In addition to known predisposing factors for HTG in HIV-infected patients (ART and immune/viral status), patients with a history of excess body weight were twice as likely to have HTG (odds ratio [OR] 2.8, 95% confidence interval [CI]: 1.1-6.9); HTG was also more frequent in patients who had a first-degree relative with cardiovascular disease (CVD) or a major risk factor for CVD (OR=3.6, CI: 1.3-9.9). Conclusion: By identifying subgroups of highly predisposed patients, appropriate lifestyle and dietary measures could be recommended on ART initiation.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 30 条
[1]   Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor [J].
Agnello, V ;
Abel, G ;
Elfahal, M ;
Knight, GB ;
Zhang, QX .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12766-12771
[2]  
*ANAES, MOD DEP DIAGN BIOL D
[3]  
Behrens G, 1998, LANCET, V351, P1958, DOI 10.1016/S0140-6736(98)26026-0
[4]   Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection [J].
Bozzette, SA ;
Ake, CF ;
Tam, HK ;
Chang, SW ;
Louis, TA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :702-710
[5]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]   Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection [J].
Collazos, J ;
Mayo, J ;
Ibarra, S ;
Cazallas, J .
AIDS, 2003, 17 (06) :927-929
[8]   PLASMA-LIPIDS IN HIV-INFECTED PATIENTS - A PROSPECTIVE-STUDY IN 95 PATIENTS [J].
CONSTANS, J ;
PELLEGRIN, JL ;
PEUCHANT, E ;
DUMON, MF ;
PELLEGRIN, I ;
SERGEANT, C ;
SIMONOFF, M ;
BROSSARD, G ;
BARBEAU, P ;
FLEURY, H ;
CLERC, M ;
LENG, B ;
CONRI, C .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1994, 24 (06) :416-420
[9]  
Duong M, 2001, J ACQ IMMUN DEF SYND, V27, P245, DOI 10.1097/00126334-200107010-00005
[10]   Hyperlipidemia associated with protease inhibitor therapy [J].
Echevarria, KL ;
Hardin, TC ;
Smith, JA .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (7-8) :859-863